The American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) are urging Congress to restore Medicare hospital outpatient payment rates for Cobalt-60-based stereotactic radiosurgery to those in place prior to the enactment of the American Taxpayer Relief Act. Under section 634 of the "fiscal cliff" legislation, payment rates for Cobalt-60- or Gamma Knife-based radiosurgery will arbitrarily be reduced to equal those of linear accelerator-based radiosurgery - despite significant cost differentials between the two technologies. Overall, the provision will cut hospital reimbursement by $300 million, decreasing the per treatment Gamma Knife reimbursement from approximately $8,100 to $3,400 - a 58-percent reduction.
Stereotactic radiosurgery was pioneered by neurosurgeons and is a procedure that utilizes externally generated ionizing radiation to inactivate or eradicate defined targets in the brain or spine without the need to make an incision. It is used to treat patients with serious brain disorders, including brain tumors, arteriovenous malformations (AVMs), pituitary adenomas and trigeminal neuralgia. Neurosurgeons perform radiosurgery using linear accelerators, particle beam accelerators and Gamma Knife units. The Gamma Knife is used to treat roughly 15,000 cases each year - 40 percent are benign tumors and functional indications and 50 percent are malignant tumors, with metastatic tumors comprising the majority of such cases.
"Neurosurgeons must have the full range of options at their disposal to effectively treat patients with serious brain disorders such as brain tumors," said AANS President Mitchel S. Berger, MD, FAANS. "We are very worried that with cuts of this magnitude, patients with brain cancer and other neurologic diseases will lose access to this important therapy."